El presente manual trata de proporcionar información sencilla, adecuada y basada en datos
científicos a los prestadores de servicios de salud, especialmente en los países de ingresos bajos y medios, para que puedan administrar tratamientos farmacológicos a las personas con trastornos mentales. ...Se espera que con este manual aumente el conocimiento y la competencia de los prestadores de servicios de salud que se hallan al frente de la prestación de asistencia sanitaria en sistemas de salud con recursos escasos.
more
Conducted November 2011 to February 2012: Summary Report
This summary report has five sections. Following the introduction (Section 1), Section 2 sets out summary findings and recommendations of the assessment team. Section 3 describes the context in which artemisinin resistance is being tackle...d. Section 4 highlights key achievements and enabling factors for the response to artemisinin resistance, whilst Section 5 provides a more detailed discussion of major issues to be addressed.
more
First edition, November 1997 | Revised July 2002
Made under Section 5 (c) of the Tanzania Food, Drugs and Cosmetics Act, 2003 | Second Edition
The Zimbabwe National Pharmacovigilance Policy Handbook, 2nd Edition updates the November 2013 version to indicate the Zimbabwe National Pharmacovigilance (PV) Centre’s compliance with the WHO Pharmacovigilance Indicators Handbook 2015.
National Tuberculosis and Leprosy Conrol Programme
L'objectif de la cartographie est d'obtenir une vision claire et précise des systèmes et politiques d'approvisionnement, de distribution et de financement des produits pharmaceutiques existants au Burkina Faso et de déterminer leur pertinence, leur cohérence et leurs forces et faiblesses en term...es d’efficacité, d’efficience, de durabilité et d’impact à long terme au regard des normes et recommandations nationales, régionales et internationales relatives à la règlementation et aux bonnes pratiques pharmaceutiques et à l'efficacité de l'aide.
more
Licensed pharmaceutical products (marketing authorization) should be manufactured only by licensed manufacturers (holders of a manufacturing authorization) whose activities are regularly inspected by competent national authorities. This guide to GMP shall be used as a standard to justify GMP status,... which constitutes one of the elements of the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce, through the assessment of applications for manufacturing authorizations and as a basis for the inspection of manufacturing facilities. It may also be used as training material for government medicines inspectors, as well as for production, QC and QA personnel in the industry
more
The purpose of this document is to provide relevant information and guidelines on
coronavirus outbreaks – and in particular the novel coronavirus SARS-CoV-2 and the
diseases it produces, COVID-19 – for pharmacists and the pharmacy workforce, both in a
primary care context (i.e. community phar...macies and primary healthcare facilities) and in
hospital settings, as well as for pharmacists working as clinical biologists in medical
analysis laboratories, for example, as clinical biologists, and offer a set of references that
may be consulted for more informationstor
more
Road safety is an issue that does not receive anywhere near the attention it deserves – and it really is one
of our great opportunities to save lives around the world
Serie: Documentos Técnico normativos
This report presents an analysis of antibacterial agents in preclinical (third annual review) and clinical (fifth annual review) development. The analysis covers traditional (direct-acting small molecules) and non-traditional antibacterial agents in development worldwide. It evaluates to what extent... the present pipeline addresses infections caused by WHO Priority Pathogens, Mycobacterium tuberculosis and Clostridioides difficile. The report also provides an assessment of the traditional agents with respect to whether they meet a set of predefined criteria for innovation, namely absence of known cross-resistance, new target, mode of action and/or class. It also includes an overview of the agents that obtained authorization since 1 July 2017.
more